Stockscreener 앱 받기
1.30
1.56%
0.02
시장 영업 전:
1.29
-0.01
-0.77%
Vivani Medical Inc 주식(VANI)의 최신 뉴스
Vivani Medical Market Sentiment - Benzinga España
Vivani Medical Inc. Revenue Breakdown – FWB:U5P - TradingView
Vivani Medical Inc (VANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - bernama
VANI|Vivani Medical Inc|Price:1.300|Chg%:+0.020 - TradingKey
Vivani Medical Inc (VANI) Cash Flow - TradingKey
Vivani Medical Inc (VANI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivani Medical Inc (VANI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to revenue forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Enterprise value to revenue forward of Vivani Medical Inc. – FWB:U5P - TradingView
Enterprise value to EBITDA forward of Vivani Medical Inc. – FWB:U5P - TradingView
ClearOne (CLRO) to acquire Cortigent, cede control to Vivani in stock deal - Stock Titan
Vivani Medical Highlights Upcoming SLIM-1 First Dosing Milestone - TipRanks
Form 4 Vivani Medical Inc For: 16 July By Investing.com - Investing.com Nigeria
Vivani Medical (NASDAQ: VANI) Targets August Human Trial For Semaglutide Implant Following Novo Nordisk Evaluation Deal - foreignpolicyjournal.com
New Form 4! Biggun at that! Hehehe - Moomoo
Vivani Medical director Gregg Williams buys $1m in stock - Investing.com UK
Vivani Medical director Gregg Williams buys $1m in stock By Investing.com - Investing.com Australia
Vivani Medical (NASDAQ: VANI) insider buys 793,650 shares at $1.26 - Stock Titan
Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentation - TradingView
Vivani Medical director, 10% owner Gregg Williams reports purchase of USD 999,999 common shares - Bitget
Vivani Medical at emerging growth conference: implant push gains traction By Investing.com - Investing.com South Africa
Vivani Medical (VANI) Emerging Growth Conference Summary - Quartr
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal - MarketBeat
Vivani Medical at emerging growth conference: implant push gains traction - Investing.com
Vivani Medical (VANI) Edges Lower in Light Trading as Support Level Comes into FocusBreakout Trade - dars.gov.et
Vivani Medical to present its GLP-1 drug implan... - Pluang
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026 - The Manila Times
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream - GlobeNewswire Inc.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss - CNBC
Vivani Medical Inc. (NASDAQ: VANI) Share Price, VANI Stock News, VANI Share Price & Updates - Kalkine
H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal - Investing.com UK
H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal By Investing.com - Investing.com South Africa
Analysts Set Expectations for Vivani Medical Q1 Earnings - MarketBeat
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $3.5 - Moomoo
Vivani Medical Inc. (VANI) Q1 2026 Earnings: EPS Beat Bolsters Investor SentimentFull Year Guidance - dars.gov.et
VANI Q1 2026 Earnings: Narrower Loss Surprise Powers 18.5% Stock JumpEarnings Revision Upgrade - dars.gov.et
Vivani Medical (VANI) Receives a Buy from Lake Street - The Globe and Mail
Vivani Advances GLP-1 Implant Program With Novo Nordisk - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
ClearOne (CLRO) surges 48% as float turns over on Cortigent merger math - TechStock²
Vivani Flat on Hookup with Novo - Baystreet.ca
Lake Street Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Sector Update: Healthcare - Moomoo
Vivani Medical Partners with Novo Nordisk to Evaluate Ultra Long-Acting Semaglutide Implant for Weight Management - Minichart
Vivani in pact with Novo to study Wegovy implant (NVO:NYSE) - Seeking Alpha
Novo Nordisk to evaluate Vivani Medical's semaglutide implant - marketscreener.com
Vivani Medical Says Novo Nordisk to Evaluate Semaglutide Implant for Weight Management - marketscreener.com
Vivani Medical to Merge Cortigent Into ClearOne; Receives 12.5M Shares, Deal Needs $10–15M Financing - TradingView
Vivani Medical Enters into Agreement with Novo Nordisk… - aapnews.aap.com.au
1.97%
0.83%
자본화:
|
볼륨(24시간):